ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; quinoline yellow aluminium lake - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; sodium lauryl sulfate; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; quinoline yellow aluminium lake; indigo carmine aluminium lake - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium lauryl sulfate; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; sunset yellow fcf aluminium lake; purified talc - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; propylene glycol; purified talc; iron oxide red; iron oxide black - rixadone is indicated for - the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,-the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; purified talc - rixadone is indicated for,- the treatment of schizophrenia and related psychoses.,- the short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,- the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see dosage and administration: behavioural disturbances in dementia).,- the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,- the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; purified talc; microcrystalline cellulose; titanium dioxide; hyprolose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; macrogol 6000 - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; croscarmellose sodium; lactose monohydrate; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; macrogol 6000; colloidal anhydrous silica - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; purified talc; hyprolose; hypromellose; magnesium stearate; macrogol 6000; croscarmellose sodium; titanium dioxide - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; docusate sodium; titanium dioxide; hypromellose; indigo carmine aluminium lake; macrogol 400 - treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 115.13 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; iron oxide yellow; sodium starch glycollate type a; silicon dioxide; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia